Careers  |  Sign In  |  Register  |   Twitter

Free CME: Oncology Rapid Response from Chicago

Advances are being rapidly made in the field of immunotherapy for the treatment of solid tumors. In this free CME, two leading clinicians will discuss studies recently presented on the use of antibodies to programmed death 1 (PD-1), programmed death ligand 1 (PDL-1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) in the treatment of cancers. The potential impact of combinations of these therapies will also be evaluated, as well as the potential for immune biomarkers to predict response to these treatments.

Click here to participate in this CME event.